Iran continues to launch missile and drone strikes across several Middle East countries as Trump warns over the Strait of Hormuz oil threats and orders an investigation into an alleged California ...

Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...

"Tax season is peak season for identity exposure. Shadow Sciences Group explains why — and what to do." The firm's analysis is drawn from its proprietary Exposure Intelligence methodology, which maps ...

While most wild animals avoid humans, a small number of species are responsible for the majority of fatal attacks each year. Some are predators by nature, while others bite or kill out of defense, ...

While previous embedding models were largely restricted to text, this new model natively integrates text, images, video, audio, and documents into a single numerical space — reducing latency by as muc ...

Canadian telecommunications giant Telus Corp. (NYSE: TU) is investigating a cybersecurity incident after unauthorized access was detected across a limited number of its internal systems. The company ...

Q4 2026 Management View CEO Tomer Weingarten highlighted that "Fiscal '26 was a landmark year for SentinelOne. We achieved $1 billion revenue scale, growing 22% year-over-year and delivered full year ...

The number of gents spending big to look their best is proof that many are just as insecure about ageing as women.

Claudia Fromond, PhD Claudia Fromond, PhD, Vect-Horus Director of Research and Development (R&D). PRESS RELEASE Senior ...

Daniel Christopher Clark Leerink Partners LLC, Research Division. All right. Great. Thank you, everybody, for joining Day 3 of the Leerink Global Healthcare Conference. I'm joined ...

Yesterday’s column was probably as dour as I get, and I regret nothing. I’m as disgusted as our readers with the Republicans in the Senate, who — with some merciful exceptions — are as gray and drab a ...

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.